Brantford General Hospital First in Canada to Offer GE Healthcare's SenoBright Contrast Enhanced Spectral Mammography (CESM) for Breast Cancer Diagnosis
Patients and clinicians alike are celebrating one of the newest arrivals at Brantford General Hospital of GE Healthcare’s innovative SenoBright* technology. The first of its kind in Canada, GE Healthcare’s new SenoBright* Contrast Enhanced Spectral Mammography (CESM) technology is designed to produce contrast-enhanced images of the breast using an x-ray contrast agent and a dual energy acquisition technique. Launched in 2010, SenoBright is already in use at numerous major mammography centres in the United States, France, Spain, Italy, Belgium, Germany, Austria, and Japan. SenoBright uses X-rays at multiple energies to create two separate but almost simultaneous exposures. The resulting images specifically illuminate and highlight the areas of contrast.
*Trademarks of the General Electric Company.
GE Healthcare Introduces New Cardiac MRI Analysis Software
GE Healthcare announced two new software packages for advanced analysis of cardiovascular magnetic resonance (MR) images: CardiacVX and MR VesselIQ Xpress. Cardiac MR can provide a wealth of information about the patient’s cardiac condition such as functional parameters, flow, and infarction. However, extracting this information and presenting it in an integrated fashion to the referring physician can be a time-consuming task for the technologist or clinician performing the study. GE Healthcare’s new CardiacVX software delivers fast, intuitive, semi-automatic analysis of key cardiac parameters, allowing the user to create a comprehensive cardiac patient report within a streamlined clinical workflow.
GE Healthcare Works to Speed Up Fight Against Cancer
GE Healthcare’s work to accelerate cancer innovation and improve care for cancer patients reached new milestones in advanced technology. The campaign is founded on GE Healthcare’s integrated portfolio, which is uniquely positioned to drive impact in oncology and a leap forward for individualized cancer care. GE Healthcare launched a series of new oncology technologies and systems to help advance cancer diagnostic and molecular imaging in 2012.
GE Healthcare Announces Centricity Practice Solution 11
GE Healthcare announced the release of Centricity* Practice Solution 11, the next generation of its fully integrated EMR and Practice Management solution. With a dynamic search engine and one-click problem entry, Centricity Practice Solution simplifies the data entry required for medical providers to comply with new the ICD-10 coding requirements and reduces the number of clicks required to enter a problem by 75%. Combined with the ability to customize workflows, this new solution will help ambulatory practices adjust to healthcare reform and embrace new care models.
New [18F]Flutemetamol Data Presented by GE Healthcare at 7th Annual Human Amyloid Imaging Conference
Study data presented by GE Healthcare at the 7th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that GE Healthcare’s electronic training program (ETP) used to teach interpretation of images taken using the investigational PET imaging agent [18F]flutemetamol was highly effective in training inexperienced readers. In the study*, five physician readers (3 nuclear medicine physicians and 2 radiologists) inexperienced in amyloid imaging and independently trained with the ETP, interpreted 305 [18F]flutemetamol image sets blinded to patient information (i.e., a forced choice between normal or abnormal for brain amyloid). For the 135 patient images for which a standard of truth in regard to histopathological brain amyloid status was available, the majority read values for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 94%, 92%, 87%, and 96% respectively. Inter-reader agreement was 81% (kappa 0.83). Intra-reader reproducibility was 93% to 100%.
*Sherwin P, Wolber J, Longenecker, F, et al. Effectiveness of an electronic training program to teach interpretation of [18F]flutemetamol PET amyloid images. Data presented at 7th Annual Human Amyloid Imaging Meeting, January 16-18, 2013.
GE Healthcare Files Supplemental New Drug Application for Its Own Manufacturing of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP)
GE Healthcare announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility. Optison is a contrast agent that mayimprove the visualization of the left ventricular border – an area of the heart that is critical to see in order to assess and diagnose certain heart diseases. Upon approval, GE Healthcare will provide supply of Optison to the US market from its manufacturing facility in Oslo, becoming the only contrast media manufacturer to produce its own stock for the US.